We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note
Read MoreHide Full Article
In the latest close session, Boston Scientific (BSX - Free Report) was down 1.84% at $42.68. The stock's change was less than the S&P 500's daily gain of 0.79%. Meanwhile, the Dow gained 0.26%, and the Nasdaq, a tech-heavy index, added 1.52%.
The stock of medical device manufacturer has fallen by 9.38% in the past month, lagging the Medical sector's gain of 7.53% and the S&P 500's loss of 1.82%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. The company is scheduled to release its earnings on July 29, 2026. In that report, analysts expect Boston Scientific to post earnings of $0.83 per share. This would mark year-over-year growth of 10.67%. Meanwhile, the latest consensus estimate predicts the revenue to be $5.39 billion, indicating a 6.54% increase compared to the same quarter of the previous year.
BSX's full-year Zacks Consensus Estimates are calling for earnings of $3.36 per share and revenue of $21.61 billion. These results would represent year-over-year changes of +9.8% and +7.65%, respectively.
Any recent changes to analyst estimates for Boston Scientific should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 0.37% fall in the Zacks Consensus EPS estimate. At present, Boston Scientific boasts a Zacks Rank of #4 (Sell).
Looking at its valuation, Boston Scientific is holding a Forward P/E ratio of 12.95. Its industry sports an average Forward P/E of 18.39, so one might conclude that Boston Scientific is trading at a discount comparatively.
We can also see that BSX currently has a PEG ratio of 0.83. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products industry had an average PEG ratio of 1.65 as trading concluded yesterday.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 180, positioning it in the bottom 27% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note
In the latest close session, Boston Scientific (BSX - Free Report) was down 1.84% at $42.68. The stock's change was less than the S&P 500's daily gain of 0.79%. Meanwhile, the Dow gained 0.26%, and the Nasdaq, a tech-heavy index, added 1.52%.
The stock of medical device manufacturer has fallen by 9.38% in the past month, lagging the Medical sector's gain of 7.53% and the S&P 500's loss of 1.82%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. The company is scheduled to release its earnings on July 29, 2026. In that report, analysts expect Boston Scientific to post earnings of $0.83 per share. This would mark year-over-year growth of 10.67%. Meanwhile, the latest consensus estimate predicts the revenue to be $5.39 billion, indicating a 6.54% increase compared to the same quarter of the previous year.
BSX's full-year Zacks Consensus Estimates are calling for earnings of $3.36 per share and revenue of $21.61 billion. These results would represent year-over-year changes of +9.8% and +7.65%, respectively.
Any recent changes to analyst estimates for Boston Scientific should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 0.37% fall in the Zacks Consensus EPS estimate. At present, Boston Scientific boasts a Zacks Rank of #4 (Sell).
Looking at its valuation, Boston Scientific is holding a Forward P/E ratio of 12.95. Its industry sports an average Forward P/E of 18.39, so one might conclude that Boston Scientific is trading at a discount comparatively.
We can also see that BSX currently has a PEG ratio of 0.83. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products industry had an average PEG ratio of 1.65 as trading concluded yesterday.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 180, positioning it in the bottom 27% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.